Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T
Status unconfirmed · Early Phase 1 · Has a placebo group
Conditions studied: Psychotropic Drugs Effects
In brief
The primary goal of this double-blind, placebo-controlled, within-subjects functional neuroimaging study is to examine the extent to which the hypnotic zolpidem decreases brain activity in regions of the brain known to process emotional information. Although zolpidem is an effective sleep-aid, its ability to engender anti-anxiety effects is equivocal, yet promising. Zolpidem's activity during tasks that engage anxiety-related processes in the brain will be compared to that of the known anxiolytic drug alprazolam, a positive comparator caffeine, and placebo. A secondary goal of this study is to compare the subjective drug effects, or how individuals feel, following the interventions. These measures will be used to determine the existence of brain-behavior relationships, thus demonstrating that imaging is an important tool for informing us about how drugs produce their effects in the brain.
Key facts
- Study ID
- NCT01747590
- Run by
- Mclean Hospital
- People needed
- 12
- Starts
- 2011-07-01
- Expected to finish
- 2013-12-01
- Last updated by the study team
- 2012-12-11
Who can join
Age: 21 and older, up to 40. Sex: any. Healthy volunteers: accepted.
Where it is running
- McLean Hospital — Belmont, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.